{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-068745","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.745630+00:00","generated_at":"2026-05-17T23:44:54.808030+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio to publish video with additional Phase 2 XPro trial findings after AAIC","bullets":["Video detailing additional MINDFuL Phase 2 findings of XPro (soluble TNF inhibitor) to be published July 31 at 4 PM ET.","Trial showed consistent cognitive and biomarker benefit after 6 months in amyloid-beta+ patients with ≥2 inflammatory blood biomarkers.","Data presented at AAIC July 29 in Toronto; corporate presentation also filed as Exhibit 99.2.","Dr. Sharon Cohen presented; VP Dr. CJ Barnum cited meaningful changes in short trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-068745","json":"https://secwatch.observer/filing/0001213900-25-068745.json","markdown":"https://secwatch.observer/filing/0001213900-25-068745.md","text":"https://secwatch.observer/filing/0001213900-25-068745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/0001213900-25-068745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/ea0250594-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:44:54.808030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}